4.5 Article

Hybrid EFR-FFR decision-making strategy: implications for enhancing universal adoption of physiology-guided coronary revascularisation

期刊

EUROINTERVENTION
卷 8, 期 10, 页码 1157-1165

出版社

EUROPA EDITION
DOI: 10.4244/EIJV8I10A179

关键词

instantaneous wave-free ratio; fractional flow reserve; physiology-guided PCI; adenosine

资金

  1. National Institute for Health Research (NIHR)
  2. Imperial College Healthcare NHS Trust Biomedical Research Centre
  3. MRC [G1000357, G1100443] Funding Source: UKRI
  4. British Heart Foundation [FS/12/15/29380, PG/11/53/28991, FS/11/46/28861, FS/10/38/28268, FS/11/43/28760] Funding Source: researchfish
  5. Medical Research Council [G1100443, G1000357] Funding Source: researchfish
  6. National Institute for Health Research [ACF-2010-21-008, CL-2006-21-003(1)] Funding Source: researchfish

向作者/读者索取更多资源

Aims: Adoption of fractional flow reserve (FFR) remains low (6-8%), partly because of the time, cost and potential inconvenience associated with vasodilator administration. The instantaneous wave-Free Ratio (iFR) is a pressure-only index of stenosis severity calculated without vasodilator drugs. Before outcome trials test iFR as a sole guide to revascularisation, we evaluate the merits of a hybrid iFR-FFR decision-making strategy for universal physiological assessment. Methods and results: Coronary pressure traces from 577 stenoses were analysed. iFR was calculated as the ratio between Pd and Pa in the resting diastolic wave-free window. A hybrid iFR-FFR strategy was evaluated, by allowing iFR to defer some stenoses (where negative predictive value is high) and treat others (where positive predictive value is high), with adenosine being given only to patients with iFR in between those values. For the most recent fixed FFR cut-off (0.8), an iFR of <0.86 could be used to confirm treatment (PPV of 92%), whilst an iFR value of >0.93 could be used to defer revascularisation (NPV of 91%). Limiting vasodilator drugs to cases with iFR values between 0.86 to 0.93 would obviate the need for vasodilator drugs in 57% of patients, whilst maintaining 95% agreement with an FFR-only strategy. If the 0.75-0.8 FFR grey zone is accounted for, vasodilator drug requirement would decrease by 76%. Conclusion: A hybrid iFR-FFR decision-making strategy for revascularisation could increase adoption of physiology-guided PCI, by more than halving the need for vasodilator administration, whilst maintaining high classification agreement with an FFR-only strategy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据